Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

被引：0
|
作者：
Jeeyun Lee
Kyung Hae Jung
Young Suk Park
Joong Bae Ahn
Sang Jun Shin
Seock-Ah Im
Do Youn Oh
Dong Bok Shin
Tae Won Kim
Namsu Lee
Jae Ho Byun
Yong Sang Hong
Joon Oh Park
Se Hoon Park
Ho Yeong Lim
Won Ki Kang
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Research Institute and Hospital,Oncology, Department of Medicine, Samsung Medical Center
[3] Yonsei University College of Medicine,Center for Colorectal Cancer, National Cancer Center
[4] Seoul National University College of Medicine,Department of Internal Medicine
[5] Gachon University Gil Medical Center,Department of Internal Medicine
[6] University of Ulsan College of Medicine,Division of Hematology and Oncology, Department of Internal Medicine
[7] Soon Chun Hyang University Hospital,Division of Oncology, Department of Medicine, Asan Medical Center
[8] The Catholic University of Korea,Division of Hematology
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 64卷
关键词：
Statin; Simvastatin; Irinotecan; Cetuximab; Lovastatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：657 / 663
页数：6
相关论文
共 50 条
  • [41] Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Meyerhardt, Jeffrey A.
    Clark, Jeffrey W.
    Supko, Jeffrey G.
    Eder, Joseph P.
    Ogino, Shuji
    Stewart, Clinton F.
    D'Amato, Ferdinando
    Dancey, Janet
    Enzinger, Peter C.
    Zhu, Andrew X.
    Ryan, David P.
    Earle, Craig C.
    Mayer, Robert J.
    Michelini, Ann
    Kinsella, Kate
    Fuchs, Charles S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (05) : 661 - 670
  • [42] Irinotecan versus infusional 5-fluorouracil: A phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil
    Van Cutsem, E
    Blijham, GH
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 13 - 20
  • [43] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer
    Ranhua Cao
    Shuai Zhang
    Dedong Ma
    Likuan Hu
    Medical Oncology, 2015, 32
  • [44] A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation
    Liu, Yuguo
    Luan, Lijuan
    Wang, Xingli
    ONCOTARGETS AND THERAPY, 2015, 8 : 1061 - 1068
  • [45] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer
    Cao, Ranhua
    Zhang, Shuai
    Ma, Dedong
    Hu, Likuan
    MEDICAL ONCOLOGY, 2015, 32 (01) : 1 - 5
  • [46] PHASE II STUDY OF OXALIPLATIN COMBINED WITH LEUCOVORIN AND 5-FLUOROURACIL AS FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Lim, J. Y.
    Cho, J. Y.
    Jeung, H.
    Kim, S. H.
    Lee, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 183 - 184
  • [47] A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer
    Pan, CX
    Loehrer, P
    Seitz, D
    Helft, P
    Juliar, B
    Ansari, R
    Pletcher, W
    Vinson, J
    Cheng, L
    Sweeney, C
    ONCOLOGY, 2005, 69 (01) : 63 - 70
  • [48] Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer
    Liang, Hong-Liang
    Hu, Ai-Ping
    Li, Sen-Lin
    Liu, Ji-Yong
    MEDICAL ONCOLOGY, 2014, 31 (06)
  • [49] 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) plus bevacizumab in patients with metastatic colo-rectal cancer: Preliminary results of a phase II trial
    Condorelli, S.
    Cordio, S.
    Rosati, G.
    Caputo, G.
    Rampello, E.
    Salice, P.
    Parra, H. J. Soto
    Tondulli, L.
    Pumo, V.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2007, 18 : 8 - 8
  • [50] Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer
    Hong-Liang Liang
    Ai-Ping Hu
    Sen-Lin Li
    Ji-Yong Liu
    Medical Oncology, 2014, 31
12345